The L-Cell in Nutritional Sensing and the Regulation of Appetite

Frontiers in Nutrition

Volumn 2, Issue , 2015, Pages

  Spreckley, Eleanor ^a   Murphy, Kevin Graeme ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

appetite; enteroendocrine; glucagon like peptide 1; macronutrient; peptide YY

Indexed keywords

EID: 84962752390     PISSN: None     EISSN: 2296861X     Source Type: Journal    
DOI: 10.3389/fnut.2015.00023     Document Type: Review

References (200)

1. Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal chemosensation. Cell Metab (2012) 15:421–31.10.1016/j.cmet.2011.12.01922482725
2. Rindi G, Leiter AB, Kopin AS, Bordi C, Solcia E. The “normal” endocrine cell of the gut: changing concepts and new evidences. Ann N Y Acad Sci (2004) 1014:1–12.10.1196/annals.1294.00115153415
3. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology (2012) 153:3054–65.10.1210/en.2011-217022685263
4. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest (2007) 117:13–23.10.1172/jci30227
5. Engelstoft MS, Egerod KL, Holst B, Schwartz TW. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab (2008) 8:447–9.10.1016/j.cmet.2008.11.00419041758
6. Bohorquez DV, Chandra R, Samsa LA, Vigna SR, Liddle RA. Characterization of basal pseudopod-like processes in ileal and colonic PYY cells. J Mol Histol (2011) 42:3–13.10.1007/s10735-010-9302-621061049
7. Bohorquez DV, Shahid RA, Erdmann A, Kreger AM, Wang Y, Calakos N, et al. Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells. J Clin Invest (2015) 125:782–6.10.1172/jci7836125555217
8. National Institute for Health and Care Excellence. Obesity: Identification, Assessment and Management of Overweight and Obesity in Children, Young People and Adults [Online]. National Institute for Health and Care Excellence (2014). Available from: http://www.nice.org.uk/guidance/cg189/chapter/1-recommendations#surgical-interventions (accessed April 2, 2015).
9. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab (2002) 283:E1173–7.10.1152/ajpendo.00233.200212388165
10. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) (2006) 30:1729–36.10.1038/sj.ijo.080334416619056
11. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes (2012) 61:2753–62.10.2337/db11-155622933116
12. FDA. FDA Approves Weight-Management Drug Saxenda [Online]. U.S. Department of Health and Human Services (2014). Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm (accessed March 31, 2015).
13. le Roux CW, Borg CM, Murphy KG, Vincent RP, Ghatei MA, Bloom SR. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem (2008) 45:93–5.10.1258/acb.2007.00706818275682
14. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes (2011) 60:1561–5.10.2337/db10-047421430088
15. Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, et al. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab (2014) 306:E1248–56.10.1152/ajpendo.00569.201324735885
16. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology (2001) 142:4244–50.10.1210/endo.142.10.843011564680
17. Adrian TE, Sagor GR, Savage AP, Bacarese-Hamilton AJ, Hall GM, Bloom SR. Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man. J Clin Endocrinol Metab (1986) 63:803–7.10.1210/jcem-63-4-8033755728
18. Pironi L, Stanghellini V, Miglioli M, Corinaldesi R, De Giorgio R, Ruggeri E, et al. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology (1993) 105:733–9.8359644
19. Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG. 5’-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem (1995) 270:27186–91.10.1074/jbc.270.45.271867592975
20. Reimann F, Williams L, Da Silva Xavier G, Rutter GA, Gribble FM. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia (2004) 47:1592–601.10.1007/s00125-004-1498-015365617
21. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 136:521–34.10.1016/j.cell.2008.11.04419203585
22. Clemmensen C, Smajilovic S, Smith EP, Woods SC, Brauner-Osborne H, Seeley RJ, et al. Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice. Endocrinology (2013) 154:3978–83.10.1210/en.2013-152923959939
23. Joshi S, Tough IR, Cox HM. Endogenous PYY and GLP-1 mediate l-glutamine responses in intestinal mucosa. Br J Pharmacol (2013) 170:1092–101.10.1111/bph.1235223992397
24. Choi S, Lee M, Shiu AL, Yo SJ, Hallden G, Aponte GW. GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells. Am J Physiol Gastrointest Liver Physiol (2007) 292:G1366–75.10.1152/ajpgi.00516.200617290006
25. Wellendorph P, Hansen KB, Balsgaard A, Greenwood JR, Egebjerg J, Brauner-Osborne H. Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol (2005) 67:589–97.10.1124/mol.104.00755915576628
26. Wellendorph P, Brauner-Osborne H. Molecular basis for amino acid sensing by family C G-protein-coupled receptors. Br J Pharmacol (2009) 156:869–84.10.1111/j.1476-5381.2008.00078.x19298394
27. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab (2008) 8:532–9.10.1016/j.cmet.2008.11.00219041768
28. Cherbut C, Ferrier L, Roze C, Anini Y, Blottiere H, Lecannu G, et al. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. Am J Physiol (1998) 275:G1415–22.9843779
29. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes (2012) 61:364–71.10.2337/db11-101922190648
30. Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond) (2014) 39(3):424–9.10.1038/ijo.2014.15325109781
31. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med (2005) 11:90–4.10.1038/nm116815619630
32. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes (2008) 57:2280–7.10.2337/db08-030718519800
33. Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sorhede Winzell M, Hammar M, et al. GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. Diabetologia (2014) 57:1182–91.10.1007/s00125-014-3213-024663807
34. Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest (1992) 22:283–91.10.1111/j.1365-2362.1992.tb01464.x1499644
35. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol (1996) 10:342–55.10.1210/mend.10.4.8721980
36. Petersen N, Reimann F, Van Es JH, Van Den Berg BM, Kroone C, Pais R, et al. Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest (2015) 125:379–85.10.1172/jci7583825500886
37. Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia (2013) 56:1413–6.10.1007/s00125-013-2887-z23519462
38. Grandt D, Schimiczek M, Struk K, Shively J, Eysselein VE, Goebell H, et al. Characterization of two forms of peptide YY, PYY(1-36) and PYY(3-36), in the rabbit. Peptides (1994) 15:815–20.10.1016/0196-9781(94)90035-37984499
39. Guarita DR, Deng X, Huh YB, Wood PG, Reeve JR, Jr Whitcomb DC. PYY regulates pancreatic exocrine secretion through multiple receptors in the awake rat. Dig Dis Sci (2000) 45:1696–702.10.1023/A:100555073214611052307
40. Larsson LI, Holst J, Hakanson R, Sundler F. Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry (1975) 44:281–90.10.1007/BF004903641102501
41. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol (1993) 138:159–66.10.1677/joe.0.13801597852887
42. Nauck MA, Siemsgluss J, Orskov C, Holst JJ. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Z Gastroenterol (1996) 34:159–66.8650968
43. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab (2007) 293:E743–53.10.1152/ajpendo.00159.2007
44. Pilichiewicz AN, Papadopoulos P, Brennan IM, Little TJ, Meyer JH, Wishart JM, et al. Load-dependent effects of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men. Am J Physiol Regul Integr Comp Physiol (2007) 293:R2170–8.10.1152/ajpregu.00511.2007
45. Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Lond) (1998) 95:325–9.10.1042/CS199800519730852
46. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci (2003) 994:162–8.10.1111/j.1749-6632.2003.tb03176.x12851312
47. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet (1987) 2:1300–4.10.1016/S0140-6736(87)91194-92890903
48. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab (2003) 88:2706–13.10.1210/jc.2002-02187312788877
49. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology (2005) 129:1430–6.10.1053/j.gastro.2005.09.00116285944
50. Ronveaux CC, De Lartigue G, Raybould HE. Ability of GLP-1 to decrease food intake is dependent on nutritional status. Physiol Behav (2014) 135:222–9.10.1016/j.physbeh.2014.06.01524955496
51. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia (2004) 47:357–66.10.1007/s00125-004-1342-614968296
52. Blache P, Kervran A, Bataille D. Oxyntomodulin and glicentin: brain-gut peptides in the rat. Endocrinology (1988) 123:2782–7.10.1210/endo-123-6-27823197645
53. Ohneda A, Ohneda K, Nagasaki T, Sasaki K. Insulinotropic action of human glicentin in dogs. Metabolism (1995) 44:47–51.10.1016/0026-0495(95)90288-07854165
54. D’Alessio DA. What if gut hormones aren’t really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract. Endocrinology (2011) 152:2925–6.10.1210/en.2011-1385
55. Smith EP, An Z, Wagner C, Lewis AG, Cohen EB, Li B, et al. The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab (2014) 19:1050–7.10.1016/j.cmet.2014.04.00524836562
56. Boey D, Lin S, Karl T, Baldock P, Lee N, Enriquez R, et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia (2006) 49:1360–70.10.1007/s00125-006-0237-016680491
57. Chandarana K, Gelegen C, Irvine EE, Choudhury AI, Amouyal C, Andreelli F, et al. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab (2013) 2:142–52.10.1016/j.molmet.2013.03.00124049729
58. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes (1996) 45:832–5.10.2337/diab.45.6.8328635662
59. Halatchev IG, Cone RD. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab (2005) 1:159–68.10.1016/j.cmet.2005.02.00316054059
60. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes (2014) 63:1224–33.10.2337/db13-144024296712
61. Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-­dependent weight loss. J Clin Invest (2014) 124:4473–88.10.1172/jci7527625202980
62. Wang Y, Perfetti R, Greig NH, Holloway HW, Deore KA, Montrose-Rafizadeh C, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest (1997) 99:2883–9.10.1172/jci1194829185511
63. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes (1998) 47:358–64.10.2337/diabetes.47.3.3589519740
64. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 48:2270–6.10.2337/diabetes.48.12.227010580413
65. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology (2000) 141:4600–5.10.1210/endo.141.12.780611108273
66. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker ­diabetic rats. Endocrinology (2002) 143:4397–408.10.1210/en.2002-22040512399437
67. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A (1996) 93:7911–6.10.1073/pnas.93.15.79118755576
68. Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, et al. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology (2003) 125:136–47.10.1016/S0016-5085(03)00667-X12851879
69. Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol (1997) 273:R1965–71.9435650
70. Au A, Gupta A, Schembri P, Cheeseman CI. Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochem J (2002) 367:247–54.10.1042/bj2002039312095416
71. Welch I, Saunders K, Read NW. Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Gastroenterology (1985) 89:1293–7.4054521
72. Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci (1995) 40:1074–82.10.1007/BF020642027729267
73. van Avesaat M, Troost FJ, Ripken D, Hendriks HF, Masclee AA. Ileal brake activation: macronutrient-specific effects on eating behavior? Int J Obes (Lond) (2015) 39(2):235–43.10.1038/ijo.2014.11224957485
74. Deng X, Guarita DR, Wood PG, Kriess C, Whitcomb DC. PYY potently inhibits pancreatic exocrine secretion mediated through CCK-secretin-stimulated pathways but not 2-DG-stimulated pathways in awake rats. Dig Dis Sci (2001) 46:156–65.10.1023/A:101238000473611270780
75. Persaud SJ, Bewick GA. Peptide YY: more than just an appetite regulator. Diabetologia (2014) 57:1762–9.10.1007/s00125-014-3292-y24917132
76. Tough IR, Forbes S, Tolhurst R, Ellis M, Herzog H, Bornstein JC, et al. Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y(1) and Y(2) receptors. Br J Pharmacol (2011) 164:471–84.10.1111/j.1476-5381.2011.01401.x21457230
77. Lloyd KC, Grandt D, Aurang K, Eysselein VE, Schimiczek M, Reeve JR, Jr. Inhibitory effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y1 receptors. Am J Physiol (1996) 270:G123–7.8772509
78. Amisten S, Salehi A, Rorsman P, Jones PM, Persaud SJ. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol Ther (2013) 139:359–91.10.1016/j.pharmthera.2013.05.00423694765
79. Tan TM, Salem V, Troke RC, Alsafi A, Field BC, De Silva A, et al. Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose. J Clin Endocrinol Metab (2014) 99:E2317–24.10.1210/jc.2014-214325144632
80. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab (1983) 57:488–95.10.1210/jcem-57-3-4886874888
81. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes (2009) 58:2258–66.10.2337/db09-0278
82. Dubrasquet M, Bataille D, Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep (1982) 2:391–5.10.1007/BF01119301
83. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology (2004) 127:546–58.10.1053/j.gastro.2004.04.06315300587
84. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology (2004) 145:2687–95.10.1210/en.2003-1338
85. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem (2003) 278:22418–23.10.1074/jbc.M21235520012690116
86. Lynch AM, Pathak N, Flatt YE, Gault VA, O’Harte FP, Irwin N, et al. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus. Eur J Pharmacol (2014) 743:69–78.10.1016/j.ejphar.2014.09.01825246014
87. Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nat Rev Neurosci (2014) 15:367–78.10.1038/nrn374524840801
88. Elias CF, Lee C, Kelly J, Aschkenasi C, Ahima RS, Couceyro PR, et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron (1998) 21:1375–85.10.1016/S0896-6273(00)80656-X9883730
89. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci (1998) 1:271–2.10.1038/1082
90. Aponte Y, Atasoy D, Sternson SM. AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. Nat Neurosci (2011) 14:351–5.10.1038/nn.273921209617
91. Atasoy D, Betley JN, Su HH, Sternson SM. Deconstruction of a neural circuit for hunger. Nature (2012) 488:172–7.10.1038/nature1127022801496
92. Schwartz GJ. The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition (2000) 16:866–73.10.1016/S0899-9007(00)00464-011054591
93. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia (2005) 48:612–5.10.1007/s00125-005-1705-7
94. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol (1996) 271:E458–64.8843738
95. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology (1999) 140:5356–63.10.1210/endo.140.11.714310537167
96. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci (2004) 110:36–43.10.1016/j.autneu.2003.11.00114766323
97. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst (1996) 61:149–54.10.1016/S0165-1838(96)00071-98946334
98. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology (2009) 150:1174–81.10.1210/en.2008-122118948395
99. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res (2005) 1044:127–31.10.1016/j.brainres.2005.03.01115862798
100. Shapiro RE, Miselis RR. The central neural connections of the area postrema of the rat. J Comp Neurol (1985) 234:344–64.10.1002/cne.9023403063988989
101. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol (1998) 274:R23–9.9458894
102. Sandoval DA, Bagnol D, Woods SC, D’Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes (2008) 57:2046–54.10.2337/db07-182418487451
103. Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology (2015) 156:255–67.10.1210/en.2014-167525380238
104. Lluis F, Fujimura M, Gomez G, Salva JA, Greeley GH, Jr Thompson JC. [Cellular localization, half-life, and secretion of peptide YY]. Rev Esp Fisiol (1989) 45:377–84.2698500
105. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382:168–71.10.1038/382168a08700207
106. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab (2007) 292:E1062–8.10.1152/ajpendo.00450.200617148749
107. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 418:650–4.10.1038/nature0266612167864
108. Chelikani PK, Haver AC, Reeve JR, Jr Keire DA, Reidelberger RD. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol (2006) 290:R298–305.10.1152/ajpregu.00674.200516210414
109. Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol (2007) 293:R39–46.10.1152/ajpregu.00164.2007
110. Challis BG, Coll AP, Yeo GS, Pinnock SB, Dickson SL, Thresher RR, et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci U S A (2004) 101:4695–700.10.1073/pnas.030693110115070780
111. Halatchev IG, Ellacott KL, Fan W, Cone RD. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology (2004) 145:2585–90.10.1210/en.2003-175415016721
112. Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology (2005) 146:2369–75.10.1210/en.2004-126615718279
113. Chelikani PK, Haver AC, Reidelberger RD. Dose-dependent effects of peptide YY(3-36) on conditioned taste aversion in rats. Peptides (2006) 27:3193–201.10.1016/j.peptides.2006.08.00116962209
114. O’Brien PE. Controversies in bariatric surgery. Br J Surg (2015) 102(6):611–8.10.1002/bjs.976025690271
115. Pedersen-Bjergaard U, Host U, Kelbaek H, Schifter S, Rehfeld JF, Faber J, et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest (1996) 56:497–503.10.3109/003655196090888058903111
116. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg (2006) 243:108–14.10.1097/01.sla.0000183349.16877.84
117. Chronaiou A, Tsoli M, Kehagias I, Leotsinidis M, Kalfarentzos F, Alexandrides TK. Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial. Obes Surg (2012) 22:1761–70.10.1007/s11695-012-0738-5
118. Kohli R, Kirby M, Setchell KD, Jha P, Klustaitis K, Woollett LA, et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol (2010) 299:G652–60.10.1152/ajpgi.00221.201020595624
119. Stearns AT, Balakrishnan A, Rhoads DB, Tavakkolizadeh A. Rapid upregulation of sodium-glucose transporter SGLT1 in response to intestinal sweet taste stimulation. Ann Surg (2010) 251:865–71.10.1097/SLA.0b013e3181d96e1f20395849
120. Helmrath MA, Fong JJ, Dekaney CM, Henning SJ. Rapid expansion of intestinal secretory lineages following a massive small bowel resection in mice. Am J Physiol Gastrointest Liver Physiol (2007) 292:G215–22.10.1152/ajpgi.00188.200616920699
121. Habegger KM, Al-Massadi O, Heppner KM, Myronovych A, Holland J, Berger J, et al. Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. Gut (2014) 63:1238–46.10.1136/gutjnl-2013-30458324107591
122. Chambers AP, Jessen L, Ryan KK, Sisley S, Wilson-Perez HE, Stefater MA, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology (2011) 141:950–8.10.1053/j.gastro.2011.05.05021699789
123. Tolhurst G, Zheng Y, Parker HE, Habib AM, Reimann F, Gribble FM. Glutamine triggers and potentiates glucagon-like peptide-1 secretion by raising cytosolic Ca2+ and cAMP. Endocrinology (2011) 152:405–13.10.1210/en.2010-095621209017
124. Cho HJ, Robinson ES, Rivera LR, McMillan PJ, Testro A, Nikfarjam M, et al. Glucagon-like peptide 1 and peptide YY are in separate storage organelles in enteroendocrine cells. Cell Tissue Res (2014) 357:63–9.10.1007/s00441-014-1886-924842049
125. Blom WA, Lluch A, Stafleu A, Vinoy S, Holst JJ, Schaafsma G, et al. Effect of a high-protein breakfast on the postprandial ghrelin response. Am J Clin Nutr (2006) 83:211–20.
126. Layman DK, Evans EM, Erickson D, Seyler J, Weber J, Bagshaw D, et al. A moderate-protein diet produces sustained weight loss and long-term changes in body composition and blood lipids in obese adults. J Nutr (2009) 139:514–21.10.3945/jn.108.09944019158228
127. Soenen S, Martens EA, Hochstenbach-Waelen A, Lemmens SG, Westerterp-Plantenga MS. Normal protein intake is required for body weight loss and weight maintenance, and elevated protein intake for additional preservation of resting energy expenditure and fat free mass. J Nutr (2013) 143:591–6.10.3945/jn.112.16759323446962
128. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab (2006) 4:223–33.10.1016/j.cmet.2006.08.00116950139
129. Lejeune MP, Westerterp KR, Adam TC, Luscombe-Marsh ND, Westerterp-Plantenga MS. Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate metabolism during a high-protein diet and measured in a respiration chamber. Am J Clin Nutr (2006) 83:89–94.16400055
130. Cordier-Bussat M, Bernard C, Levenez F, Klages N, Laser-Ritz B, Philippe J, et al. Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes (1998) 47:1038–45.10.2337/diabetes.47.7.10389648826
131. Choi S, Lee M, Shiu AL, Yo SJ, Aponte GW. Identification of a protein hydrolysate responsive G protein-coupled receptor in enterocytes. Am J Physiol Gastrointest Liver Physiol (2007) 292:G98–112.10.1152/ajpgi.00295.200616935853
132. Diakogiannaki E, Pais R, Tolhurst G, Parker HE, Horscroft J, Rauscher B, et al. Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptor. Diabetologia (2013) 56:2688–96.10.1007/s00125-013-3037-324045836
133. Will MJ, Franzblau EB, Kelley AE. Nucleus accumbens mu-opioids regulate intake of a high-fat diet via activation of a distributed brain network. J Neurosci (2003) 23:2882–8.12684475
134. Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil (2004) 16(Suppl 2):3–16.10.1111/j.1743-3150.2004.00553.x
135. Duraffourd C, De Vadder F, Goncalves D, Delaere F, Penhoat A, Brusset B, et al. Mu-opioid receptors and dietary protein stimulate a gut-brain neural circuitry limiting food intake. Cell (2012) 150:377–88.10.1016/j.cell.2012.05.03922771138
136. Mithieux G, Misery P, Magnan C, Pillot B, Gautier-Stein A, Bernard C, et al. Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab (2005) 2:321–9.10.1016/j.cmet.2005.09.01016271532
137. Mace OJ, Schindler M, Patel S. The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J Physiol (2012) 590:2917–36.10.1113/jphysiol.2011.22380022495587
138. Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, et al. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem (2005) 280:40201–9.10.1074/jbc.M50518620016199532
139. Wellendorph P, Brauner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene (2004) 335:37–46.10.1016/j.gene.2004.03.00315194188
140. Kuang D, Yao Y, Lam J, Tsushima RG, Hampson DR. Cloning and characterization of a family C orphan G-protein coupled receptor. J Neurochem (2005) 93:383–91.10.1111/j.1471-4159.2005.03025.x15816861
141. Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B, Luo J, et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One (2008) 3:e3858.10.1371/journal.pone.000385819050760
142. Wellendorph P, Johansen LD, Jensen AA, Casanova E, Gassmann M, Deprez P, et al. No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions. J Mol Endocrinol (2009) 42:215–23.10.1677/jme-08-014919103720
143. Oya M, Kitaguchi T, Pais R, Reimann F, Gribble F, Tsuboi T. The G protein-­coupled receptor family C group 6 subtype A (GPRC6A) receptor is involved in amino acid-induced glucagon-like peptide-1 secretion from GLUTag cells. J Biol Chem (2013) 288:4513–21.10.1074/jbc.M112.40267723269670
144. Kinsey-Jones J, Alamshah A, McGavigan A, Spreckley E, Banks K, Monteoliva N, et al. GPRC6A is not required for the effects of a high protein diet on body weight in mice. Obesity (Silver Spring) (2015) 23(6):1194–200.
145. Hoon MA, Adler E, Lindemeier J, Battey JF, Ryba NJ, Zuker CS. Putative mammalian taste receptors: a class of taste-specific GPCRs with distinct topographic selectivity. Cell (1999) 96:541–51.10.1016/S0092-8674(00)80658-310052456
146. Li X, Staszewski L, Xu H, Durick K, Zoller M, Adler E. Human receptors for sweet and umami taste. Proc Natl Acad Sci U S A (2002) 99:4692–6.10.1073/pnas.07209019911917125
147. Nelson G, Hoon MA, Chandrashekar J, Zhang Y, Ryba NJ, Zuker CS. Mammalian sweet taste receptors. Cell (2001) 106:381–90.10.1016/S0092-8674(01)00451-211509186
148. Nelson G, Chandrashekar J, Hoon MA, Feng L, Zhao G, Ryba NJ, et al. An amino-acid taste receptor. Nature (2002) 416:199–202.10.1038/nature726
149. Kinnamon SC, Vandenbeuch A. Receptors and transduction of umami taste stimuli. Ann N Y Acad Sci (2009) 1170:55–9.10.1111/j.1749-6632.2009.04106.x
150. Kim MR, Kusakabe Y, Miura H, Shindo Y, Ninomiya Y, Hino A. Regional expression patterns of taste receptors and gustducin in the mouse tongue. Biochem Biophys Res Commun (2003) 312:500–6.10.1016/j.bbrc.2003.10.13714637165
151. Dyer J, Salmon KS, Zibrik L, Shirazi-Beechey SP. Expression of sweet taste receptors of the T1R family in the intestinal tract and enteroendocrine cells. Biochem Soc Trans (2005) 33:302–5.10.1042/bst033030215667333
152. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A (2007) 104:15069–74.10.1073/pnas.070689010417724330
153. Symonds EL, Peiris M, Page AJ, Chia B, Dogra H, Masding A, et al. Mechanisms of activation of mouse and human enteroendocrine cells by nutrients. Gut (2014) 64(4):618–26.10.1136/gutjnl-2014-30683425015642
154. Conn PJ. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci (2003) 1003:12–21.10.1196/annals.1300.002
155. Bertolo RF, Burrin DG. Comparative aspects of tissue glutamine and proline metabolism. J Nutr (2008) 138:2032s–9s.18806120
156. Delgado TC. Glutamate and GABA in appetite regulation. Front Endocrinol (2013) 4:103.10.3389/fendo.2013.0010323966982
157. Wilmore DW. The effect of glutamine supplementation in patients following elective surgery and accidental injury. J Nutr (2001) 131:2543S–9S.11533310
158. van der Hulst RR, Van Kreel BK, Von Meyenfeldt MF, Brummer RJ, Arends JW, Deutz NE, et al. Glutamine and the preservation of gut integrity. Lancet (1993) 341:1363–5.10.1016/0140-6736(93)90939-E
159. Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. JPEN J Parenter Enteral Nutr (1986) 10:227–38.10.1177/0148607186010002227
160. Visek WJ. Arginine needs, physiological state and usual diets. A reevaluation. J Nutr (1986) 116:36–46.3080558
161. Wu G, Morris SM, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 336(Pt 1):1–17.
162. Aguilar-Parada E, Eisentraut AM, Unger RH. Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci (1969) 257:415–9.10.1097/00000441-196906000-00008
163. Sener A, Lebrun P, Blachier F, Malaisse WJ. Stimulus-secretion coupling of arginine-induced insulin release. Insulinotropic action of agmatine. Biochem Pharmacol (1989) 38:327–30.10.1016/0006-2952(89)90044-02643944
164. Clemmensen C, Smajilovic S, Wellendorph P, Brauner-Osborne H. The GPCR, class C, group 6, subtype A (GPRC6A) receptor: from cloning to physiological function. Br J Pharmacol (2014) 171:1129–41.10.1111/bph.1236524032653
165. Clemmensen C, Madsen AN, Smajilovic S, Holst B, Brauner-Osborne H. L-arginine improves multiple physiological parameters in mice exposed to diet-induced metabolic disturbances. Amino Acids (2012) 43:1265–75.10.1007/s00726-011-1199-122200933
166. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A (2005) 102:14238–43.10.1073/pnas.050692510216176982
167. Blomstrand E, Eliasson J, Karlsson HK, Kohnke R. Branched-chain amino acids activate key enzymes in protein synthesis after physical exercise. J Nutr (2006) 136:269s–73s.16365096
168. Crespo JL, Hall MN. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2002) 66:579–91.10.1128/MMBR.66.4.579-591.200212456783
169. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 115:577–90.10.1016/S0092-8674(03)00929-214651849
170. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 30:214–26.10.1016/j.molcel.2008.03.00318439900
171. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem (2007) 282:30107–19.10.1074/jbc.M70532520017711846
172. Harvey KF, Mattila J, Sofer A, Bennett FC, Ramsey MR, Ellisen LW, et al. FOXO-regulated transcription restricts overgrowth of Tsc mutant organs. J Cell Biol (2008) 180:691–6.10.1083/jcb.20071010018299344
173. Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol (2009) 15:4137–42.10.3748/wjg.15.413719725147
174. Mace OJ, Affleck J, Patel N, Kellett GL. Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2. J Physiol (2007) 582:379–92.10.1113/jphysiol.2007.13090617495045
175. Rodin J, Wack J, Ferrannini E, Defronzo RA. Effect of insulin and glucose on feeding behavior. Metabolism (1985) 34:826–31.10.1016/0026-0495(85)90106-4
176. Stewart SL, Black RM, Wolever TMS, Anderson GH. The relationship between the glycaemic response to breakfast cereals and subjective appetite and food intake. Nutr Res (1997) 17:1249–60.10.1016/S0271-5317(97)00108-5
177. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 292:1724–37.10.1001/jama.292.14.172415479938
178. Hediger MA, Kanai Y, You G, Nussberger S. Mammalian ion-coupled solute transporters. J Physiol (1995) 482:7s–17s.10.1113/jphysiol.1995.sp0205597730974
179. Dyer J, Hosie KB, Shirazi-Beechey SP. Nutrient regulation of human intestinal sugar transporter (SGLT1) expression. Gut (1997) 41:56–9.10.1136/gut.41.1.569274472
180. Stumpel F, Burcelin R, Jungermann K, Thorens B. Normal kinetics of intestinal glucose absorption in the absence of GLUT2: evidence for a transport pathway requiring glucose phosphorylation and transfer into the endoplasmic reticulum. Proc Natl Acad Sci U S A (2001) 98:11330–5.10.1073/pnas.21135769811562503
181. Moriya R, Shirakura T, Ito J, Mashiko S, Seo T. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab (2009) 297:E1358–65.10.1152/ajpendo.00412.200919808907
182. Nielsen LB, Ploug KB, Swift P, Orskov C, Jansen-Olesen I, Chiarelli F, et al. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol (2007) 156:663–71.10.1530/eje-06-075617535866
183. Fujita Y, Wideman RD, Speck M, Asadi A, King DS, Webber TD, et al. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am J Physiol Endocrinol Metab (2009) 296:E473–9.10.1152/ajpendo.90636.200819106249
184. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab (2006) 3:167–75.10.1016/j.cmet.2006.02.00416517404
185. Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology (2007) 148:2601–9.10.1210/en.2006-160817289847
186. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes (2009) 58:1058–66.10.2337/db08-123719208912
187. Lan H, Lin HV, Wang CF, Wright MJ, Xu S, Kang L, et al. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol (2012) 165:2799–807.10.1111/j.1476-5381.2011.01754.x22029751
188. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 425:90–3.10.1038/nature0192112955147
189. Chepurny OG, Bertinetti D, Diskar M, Leech CA, Afshari P, Tsalkova T, et al. Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag. Mol Endocrinol (2013) 27:1267–82.10.1210/me.2013-102923798572
190. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol (2009) 201:219–30.10.1677/joe-08-045319282326
191. Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res (2009) 30:149–56.10.2220/biomedres.30.14919574715
192. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 278:25481–9.10.1074/jbc.M30140320012711604
193. Karaki S, Tazoe H, Hayashi H, Kashiwabara H, Tooyama K, Suzuki Y, et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J Mol Histol (2008) 39:135–42.10.1007/s10735-007-9145-y17899402
194. Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. Nutr Rev (2001) 59:129–39.10.1111/j.1753-4887.2001.tb07001.x
195. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut (2014).10.1136/gutjnl-2014-30791325500202
196. Ichimura A, Hasegawa S, Kasubuchi M, Kimura I. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol (2014) 5:236.10.3389/fphar.2014.0023625414667
197. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature (2003) 422:173–6.10.1038/nature0147812629551
198. Haber EP, Ximenes HM, Procopio J, Carvalho CR, Curi R, Carpinelli AR. Pleiotropic effects of fatty acids on pancreatic beta-cells. J Cell Physiol (2003) 194:1–12.10.1002/jcp.1018712447984
199. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab (2005) 1:245–58.10.1016/j.cmet.2005.03.00716054069
200. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature (2012) 483:350–4.10.1038/nature1079822343897